125 related articles for article (PubMed ID: 22715163)
21. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways.
Nölting S; Maurer J; Spöttl G; Aristizabal Prada ET; Reuther C; Young K; Korbonits M; Göke B; Grossman A; Auernhammer CJ
PLoS One; 2015; 10(12):e0143830. PubMed ID: 26636335
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma.
Leinhäuser I; Richter A; Lee M; Höfig I; Anastasov N; Fend F; Ercolino T; Mannelli M; Gimenez-Roqueplo AP; Robledo M; de Krijger R; Beuschlein F; Atkinson MJ; Pellegata NS
Oncotarget; 2015 Nov; 6(36):39111-26. PubMed ID: 26337467
[TBL] [Abstract][Full Text] [Related]
23. Target therapy in metastatic pheochromocytoma: current perspectives and controversies.
Mohammed AA; El-Shentenawy AM; Sherisher MA; El-Khatib HM
Oncol Rev; 2014 Sep; 8(2):249. PubMed ID: 25992237
[TBL] [Abstract][Full Text] [Related]
24. Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
Fliedner SM; Engel T; Lendvai NK; Shankavaram U; Nölting S; Wesley R; Elkahloun AG; Ungefroren H; Oldoerp A; Lampert G; Lehnert H; Timmers H; Pacak K
PLoS One; 2014; 9(5):e97712. PubMed ID: 24846270
[TBL] [Abstract][Full Text] [Related]
25. Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.
Nölting S; Giubellino A; Tayem Y; Young K; Lauseker M; Bullova P; Schovanek J; Anver M; Fliedner S; Korbonits M; Göke B; Vlotides G; Grossman A; Pacak K
Endocrinology; 2014 Jul; 155(7):2377-90. PubMed ID: 24762141
[TBL] [Abstract][Full Text] [Related]
26. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.
Martucci VL; Pacak K
Curr Probl Cancer; 2014; 38(1):7-41. PubMed ID: 24636754
[No Abstract] [Full Text] [Related]
27. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
Vicha A; Taieb D; Pacak K
Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
[TBL] [Abstract][Full Text] [Related]
28. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.
Dahia PL
Nat Rev Cancer; 2014 Feb; 14(2):108-19. PubMed ID: 24442145
[TBL] [Abstract][Full Text] [Related]
29. The adrenal medulla and extra-adrenal paraganglia: then and now.
Tischler AS; Pacak K; Eisenhofer G
Endocr Pathol; 2014 Mar; 25(1):49-58. PubMed ID: 24362581
[TBL] [Abstract][Full Text] [Related]
30. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.
Vicha A; Musil Z; Pacak K
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210
[TBL] [Abstract][Full Text] [Related]
31. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
32. New perspectives in glioblastoma antiangiogenic therapy.
Popescu AM; Purcaru SO; Alexandru O; Dricu A
Contemp Oncol (Pozn); 2016; 20(2):109-18. PubMed ID: 27358588
[TBL] [Abstract][Full Text] [Related]
33. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
Nölting S; Garcia E; Alusi G; Giubellino A; Pacak K; Korbonits M; Grossman AB
J Mol Endocrinol; 2012 Oct; 49(2):79-96. PubMed ID: 22715163
[TBL] [Abstract][Full Text] [Related]
34. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
35. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
Ou DL; Lee BS; Lin LI; Liou JY; Liao SC; Hsu C; Cheng AL
Mol Cancer; 2014 Jan; 13():2. PubMed ID: 24387108
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
